CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
COBIOPHAD aims to create an innovative in vitro diagnostic device for identifying IgE-mediated drug allergies, particularly to beta-lactam antibiotics. By utilizing advanced biophotonic technology, the project seeks to enhance diagnostic accuracy, speed, and cost-effectiveness, ultimately improving patient safety.
Drug hypersensitivity to antibiotics, mainly Beta-lactams (BLCs) affects more than 2.5 million European citizens.
Moreover, preventable adverse drug reactions are estimated in additional hospitalization costs of 1750-4500 €/patient.
Currently, the allergy diagnosis is mainly based on the information given by invasive, single, and risky in vivo assays.
In daily practice, few in vitro diagnostic methods are available and only used at the tertiary health services.
These tests also lack of sensitivi…
UNIVERSITAT POLITECNICA DE VALENCIA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, LONDON
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER
France, Montpellier
Type: Research institute
Activity type: Research Organisations
SME: No
United Kingdom, LONDON
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, NEUSS
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
